Victory Capital Management
AXSM icon

Victory Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Victory Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
4,978
+61
+1% +$13.2K ﹤0.01% 1816
2026
Q1 		$831K Buy
4,917
+141
+3% +$24.4K ﹤0.01% 1907
2025
Q4 		$872K Buy
4,776
+36
+0.8% +$5.03K ﹤0.01% 1890
2025
Q3 		$576K Sell
4,740
-83
-2% -$9.35K ﹤0.01% 2015
2025
Q2 		$503K Sell
4,823
-10
-0.2% -$1.06K ﹤0.01% 2059
2025
Q1 		$564K Sell
4,833
-67
-1% -$7.63K ﹤0.01% 1999
2024
Q4 		$415K Sell
4,900
-60
-1% -$5.52K ﹤0.01% 2075
2024
Q3 		$446K Sell
4,960
-75
-1% -$6.55K ﹤0.01% 2041
2024
Q2 		$405K Sell
5,035
-71
-1% -$5.26K ﹤0.01% 2028
2024
Q1 		$407K Sell
5,106
-102
-2% -$8.56K ﹤0.01% 2044
2023
Q4 		$415K Sell
5,208
-13,726
-72% -$918K ﹤0.01% 2044
2023
Q3 		$1.32M Buy
18,934
+15,176
+404% +$1.13M ﹤0.01% 1526
2023
Q2 		$270K Sell
3,758
-86
-2% -$6.34K ﹤0.01% 2138
2023
Q1 		$237K Buy
3,844
+185
+5% +$12.2K ﹤0.01% 2206
2022
Q4 		$282K Buy
+3,659
New +$219K ﹤0.01% 2187
2021
Q3 		– Sell
-4,441
Closed -$300K – 2781
2021
Q2 		$300K Sell
4,441
-117
-3% -$7.02K ﹤0.01% 2412
2021
Q1 		$258K Sell
4,558
-2,541
-36% -$179K ﹤0.01% 2452
2020
Q4 		$578K Sell
7,099
-1,598
-18% -$119K ﹤0.01% 2008
2020
Q3 		$620K Buy
8,697
+928
+12% +$72.3K ﹤0.01% 1884
2020
Q2 		$639K Sell
7,769
-3,441
-31% -$265K ﹤0.01% 1903
2020
Q1 		$659K Sell
11,210
-2,477
-18% -$202K ﹤0.01% 1746
2019
Q4 		$1.42M Buy
13,687
+4,665
+52% +$188K ﹤0.01% 1640
2019
Q3 		$183K Buy
+9,022
New +$232K ﹤0.01% 2246

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Victory Capital Management's AXSM Position: Q2 2026 in Review

Victory Capital Management increased its Axsome Therapeutics (AXSM) stake by 1.2% in Q2 2026, buying an estimated $13.2K and bringing the position to 4,978 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1816.

Victory Capital Management first reported a position in AXSM in Q3 2019 and has held it in 23 quarters since. The position peaked at $1.42M in Q4 2019. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Victory Capital Management held 4,978 shares of Axsome Therapeutics worth $1.22M as of Q2 2026.
  • Victory Capital Management bought 61 Axsome Therapeutics shares in Q2 2026, an estimated $13.2K.
  • Axsome Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1816 holding.
  • Victory Capital Management first reported a position in Axsome Therapeutics in Q3 2019 and has held it in 23 quarters since.
  • Victory Capital Management's Axsome Therapeutics position peaked at $1.42M in Q4 2019.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.